OK Biotech Co., Ltd. (TPE:4155)
Taiwan · Delayed Price · Currency is TWD 15.15
+0.30 (2.02%)
Sep 18, 2026, 1:30 PM CST
OK Biotech Ratios and Metrics
Market cap in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 17, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 2,078 | 2,050 | 3,007 | 3,656 | 2,643 | 2,217 | |
Market Cap Growth | -4.74% | -31.83% | -17.75% | 38.36% | 19.21% | -12.17% |
Enterprise Value | 2,796 | 2,882 | 3,384 | 3,420 | 2,738 | 2,319 |
Last Close Price | 15.15 | 14.50 | 20.09 | 24.35 | 22.82 | 18.51 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 17, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 9.06 | 24.87 | 32.00 | 1240.26 | 18.42 | 51.00 |
Forward PE | - | 16.30 | 16.30 | 16.30 | 16.30 | 16.30 |
PS Ratio | 1.35 | 1.32 | 1.80 | 3.07 | 1.78 | 1.76 |
PB Ratio | 0.81 | 0.80 | 1.17 | 1.53 | 1.43 | 1.30 |
P/TBV Ratio | 1.01 | 1.00 | 1.49 | 1.54 | 1.46 | 1.34 |
P/OCF Ratio | 4.23 | 6.43 | 45.63 | 1246.60 | 10.99 | 101.24 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 17, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 1.82 | 1.85 | 2.03 | 2.87 | 1.85 | 1.84 |
EV/EBITDA Ratio | 8.88 | 15.38 | 27.02 | 56.71 | 16.50 | 38.83 |
EV/EBIT Ratio | 12.49 | 26.71 | 59.15 | - | 26.89 | 286.69 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 17, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.41 | 0.39 | 0.28 | 0.14 | 0.42 | 0.43 |
Debt / EBITDA Ratio | 3.35 | 5.05 | 5.57 | 5.23 | 4.60 | 11.49 |
Net Debt / Equity Ratio | 0.26 | 0.27 | 0.17 | -0.01 | 0.08 | 0.05 |
Net Debt / EBITDA Ratio | 2.20 | 3.66 | 3.43 | -0.55 | 0.87 | 1.49 |
Net Debt / FCF Ratio | 2.63 | -7.60 | -1.38 | 0.08 | -3.11 | -1.56 |
Asset Turnover | 0.40 | 0.41 | 0.49 | 0.39 | 0.51 | 0.47 |
Inventory Turnover | 2.25 | 2.29 | 3.02 | 2.44 | 2.85 | 2.97 |
Quick Ratio | 1.51 | 1.35 | 1.18 | 1.48 | 1.26 | 1.50 |
Current Ratio | 2.40 | 2.28 | 1.98 | 2.28 | 1.84 | 2.13 |
Return on Equity (ROE) | 10.29% | 3.78% | 4.29% | -0.07% | 7.70% | 1.83% |
Return on Assets (ROA) | 3.59% | 1.79% | 1.06% | -0.25% | 2.17% | 0.19% |
Return on Invested Capital (ROIC) | 5.96% | 3.22% | 1.79% | 0.11% | 4.19% | 0.34% |
Return on Capital Employed (ROCE) | 6.40% | 3.30% | 1.90% | -0.50% | 4.60% | 0.40% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 17, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 11.66% | 4.02% | 3.13% | 0.08% | 5.43% | 1.96% |
FCF Yield | 12.09% | -4.40% | -10.33% | -11.67% | -1.75% | -2.58% |
Dividend Yield | 1.98% | 2.07% | 1.49% | 1.23% | 4.89% | 4.90% |
Payout Ratio | 18.08% | 53.11% | - | 4906.38% | 66.17% | 303.37% |
Buyback Yield / Dilution | -2.31% | 0.35% | -14.02% | 1.41% | -9.95% | -18.84% |
Total Shareholder Return | -0.33% | 2.42% | -12.53% | 2.64% | -5.06% | -13.94% |